Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415073 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
A Phase 2 study, sponsored by Syndax Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04415073: Clinical Trial Phase 2 study, sponsored by Syndax Pharmaceuticals.
NCT04415073 is a Phase 2 study that was terminated before completion, run by Syndax Pharmaceuticals. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04415073, a Phase 2 study, was terminated before completion, sponsored by Syndax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.
Primary Outcome
Respiratory failure was defined by need for mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation \>6 liters oxygen/minute, or clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision-making was driven solely by resource limitation.
Interventions
- DRUG Placebo
- DRUG SNDX-6352
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-05-30 |
| Est. Completion | 2020-07-13 |
| Phase | Phase 2 |
Why NCT04415073 stopped before completion
NCT04415073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04415073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04415073 about?
NCT04415073 is a clinical study titled "A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19". This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.
What is the current status of trial NCT04415073?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-05-30. Estimated completion is 2020-07-13.
What interventions are being tested in trial NCT04415073?
The interventions under investigation include: Placebo (DRUG), SNDX-6352 (DRUG).
Who is sponsoring clinical trial NCT04415073?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04415073's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI